Delay in launch of prior authorization for Lutathera until November 1, 2018

On June 1, 2018, Anthem Blue Cross (Anthem) mailed notices to its participating providers announcing the new Medical Policy DRUG.00098 Lutetium Lu 177 (Lutathera®), a therapeutic radiopharmaceutical agent for the treatment of gastroenteropancreatic neuroendocrine tumors and other indications. Prior authorization is required for local and ASO Anthem members who have these services medically managed by AIM Specialty Health® (AIM), a separate company.  Please be aware that the program start of September 1, 2018, has been delayed. The new implementation date is November 1, 2018.